Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Launched by CENTRO HOSPITALAR DE VILA NOVA DE GAIA/ESPINHO, E.P.E. · Mar 11, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
The CIRCADIAN trial is a study looking at how the timing of a specific treatment, called pembrolizumab, affects its effectiveness in women with triple-negative breast cancer (TNBC). This is a type of breast cancer that can be harder to treat. The researchers want to see if giving this treatment at different times of the day leads to better results in shrinking tumors before surgery, which is known as achieving a pathological complete response (pCR).
To participate in this trial, women between the ages of 18 and 75 who have been diagnosed with Stage II or III TNBC and are eligible for specific pre-surgery treatments may qualify. Participants will receive pembrolizumab along with chemotherapy and will be assigned to receive their treatment either in the morning or the evening. The trial is currently recruiting participants, and it’s important to know that those who cannot fully understand the study or who may not be able to complete their treatments as planned will not be eligible. This study aims to find the best way to improve treatment outcomes for women facing this challenging diagnosis.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female sex
- • Age 18 - 75 years old
- • Diagnosed with Stage II or III TNBC and candidates for neoadjuvant treatment with ChT+pembrolizumab after multidisciplinary group discussion.
- Exclusion Criteria:
- • Patients unable to understand or consent to the study;
- • Patients not completing ≥2 cycles of planned neoadjuvant pembrolizumab cycles or ≥50% of planned neoadjuvant ChT cycles;
- • Patients under daily ≥10 mg of prednisolone or equivalent
About Centro Hospitalar De Vila Nova De Gaia/Espinho, E.P.E.
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. is a prominent healthcare institution in Portugal, dedicated to delivering high-quality medical services and advancing clinical research. With a focus on patient-centered care, the hospital integrates cutting-edge medical technology and a multidisciplinary approach to enhance treatment outcomes. As a clinical trial sponsor, it actively participates in innovative research initiatives aimed at improving therapeutic options and contributing to the broader scientific community. The institution is committed to ethical practices and rigorous compliance with regulatory standards, ensuring the safety and well-being of trial participants while fostering advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vila Nova De Gaia, Região, Portugal
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported